Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Leases (2024 - 2025)

Denali Therapeutics (DNLI) has disclosed Capital Leases for 2 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Capital Leases fell 1.37% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.6 million, a 1.37% decrease, with the full-year FY2024 number at $5.6 million, changed N/A from a year prior.
  • Capital Leases was $5.6 million for Q3 2025 at Denali Therapeutics, roughly flat from $5.6 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $5.6 million in Q3 2024 to a low of $5.6 million in Q3 2025.